Indeed, recent evidence has demonstrated that USP7 inhibition can stabilize the IκBα inhibitor, causing the arrest of the NF-κB pathway and restoring tumor cell sensitivity to bortezomib. The gene discussed is USP7; the disease is neoplasm.